H.C. Wainwright analyst Yi Chen raised the firm’s price target on Oculis (OCS) to $36 from $33 and keeps a Buy rating on the shares. The firm says privosegtor may be priced above $100,000 per treatment if successfully developed and approved.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology
- Oculis Holding: Strategic Advancements and Market Potential Drive Buy Rating
- Oculis initiated with a Buy at Needham
- Nvidia reportedly stops H20 AI chip output for China: Morning Buzz
- Oculis price target raised to $33 from $32 at H.C. Wainwright